NCT03778931 2025-09-15EMERALDStemline Therapeutics, Inc.Phase 3 Completed478 enrolled 16 charts 1 FDA
NCT06126575 2024-11-19A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic FunctionStemline Therapeutics, Inc.Phase 1 Completed16 enrolled
NCT02650817 2022-08-18Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast CancerStemline Therapeutics, Inc.Phase 1 Completed16 enrolled